The Association Between Hospital Length of Stay and Treatment With IV Magnesium in Patients With Status Migrainosus

Area of Science:

• Neurology
• Pharmacology

Background:

• Status migrainosus (SM) is a debilitating migraine subtype characterized by prolonged, severe headaches.
• Intravenous (IV) magnesium is frequently utilized in clinical settings for migraine management.
• Limited data exists on the efficacy of IV magnesium in treating status migrainosus.

Purpose of the Study:

• To investigate the association between IV magnesium therapy and length of hospital admission in patients diagnosed with status migrainosus.
• To evaluate the impact of magnesium treatment on patient outcomes in a real-world clinical setting.

Main Methods:

• Retrospective cohort study analyzing patient charts from a military treatment facility (October 2013 - December 2018).
• Inclusion criteria: patients admitted with a primary diagnosis of migraine.
• Data collected included demographic information, treatment received (IV magnesium), and length of hospital stay.

Main Results:

• Of 141 eligible patients, 46.8% received IV magnesium therapy.
• IV magnesium administration was not significantly associated with a shorter length of hospital admission (p = 0.47).
• In a subgroup without neurology consultation, magnesium showed a trend towards shorter admission, but did not reach statistical significance (p = 0.0534).

Conclusions:

• This study found no significant association between IV magnesium therapy and reduced hospital stay duration for status migrainosus.
• The findings contribute to the limited evidence base regarding magnesium's effectiveness in prolonged migraine treatment.
• Prospective studies are warranted to definitively assess magnesium therapy's role in managing status migrainosus.